Sun Pharma to Present Pivotal UNLOXCYT Data at ASCO 2026 Annual Meeting
Sun Pharma will present pivotal long-term follow-up data on UNLOXCYT™ (cosibelimab-ipdl) at the ASCO 2026 Annual Meeting on May 31, 2026. Investigator-reviewed data showed a 50% objective response rate, including 27% complete responses, with durable responses. Safety profile was manageable, with Grade ≥3 irAEs in 2% of patients.
The presentation of pivotal data at a major oncology conference like ASCO can positively influence the perception and future market potential of the drug, impacting the company's oncology portfolio.
The announcement presents positive clinical trial data for UNLOXCYT, indicating efficacy and durability of response, which is beneficial for patients with laCSCC.
Sun Pharmaceutical Industries Limited announced it will present updated results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) expansion cohort of the pivotal CK-301-101 trial of UNLOXCYT™ (cosibelimab-ipdl) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026, in Chicago.
The data presentation will include investigator-reviewed findings from 64 patients with laCSCC who received UNLOXCYT. The median age of patients was 77 years, with 66% being male. Patients received a median of 29 doses over a median treatment duration of 60 weeks. The objective response rate was 50%, comprising 17 (27%) complete responses and 15 (23%) partial responses. With a median follow-up of 31 months, responses were durable, and the median duration of response had not yet been reached.
Key safety findings indicated that the most common adverse events were anemia and diarrhea (27% each). Immune-related adverse reactions (irAEs) were observed in 34% of patients, with Grade ≥3 irAEs occurring in 1 (2%) patient, which were dermatologic and considered treatment-related. Treatment-emergent adverse events (TEAEs) were reported in 95% of patients, with 11% considered treatment-related and none fatal. Grade ≥3 TEAEs were reported in 41% of patients, with 11% considered treatment-related.
UNLOXCYT (cosibelimab-ipdl) is indicated for adults with metastatic or locally advanced CSCC who are not candidates for curative surgery or radiation. The recommended dosage is 1,200 mg intravenously over 60 minutes every 3 weeks, though a trial regimen of 800 mg every 2 weeks was also analyzed for safety. The company will also provide details on the poster presentation, including the title, session, abstract number, poster board number, date and time (May 31, 2026; 9:00 am-12:00 pm CDT), and presenter (Dr. Rahul Ladwa).
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.